Professor Saye Khoo, MD, PhD, is Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the Institute of Translational Medicine at the University of Liverpool.
His research focuses on the pharmacology of HIV treatment failure and how therapy may be improved through individualised care through understanding of why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics and drug interactions), and identify vulnerable groups who are at particular risk of failure, or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population-based modelling approaches.
He leads an active clinical pharmacology research programme and is currently Chief Investigator of the multinational DolPHIN 2 consortium, which seeks to reduce mother to child transmission of HIV through investigating the safety and efficacy of dolutegravir in late pregnancy. ()
He is co-founder and clinical lead of the internationally renowned HIV and Hepatitis Drug Interactions prescribing resources (, )